Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$32.51 USD
-4.22 (-11.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $32.50 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for Apellis Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -528.63 | -652.17 | -746.35 | -344.87 | -304.71 |
Depreciation/Amortization & Depletion | 28.00 | 1.95 | 2.46 | 16.17 | 2.58 |
Net Change from Assets/Liabilities | -200.17 | -15.70 | -93.52 | 19.59 | 53.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 106.07 | 152.18 | 274.29 | 148.63 | 37.84 |
Net Cash From Operating Activities | -594.74 | -513.75 | -563.13 | -160.49 | -211.14 |
Property & Equipment | -0.67 | -1.52 | -1.10 | -5.42 | -1.69 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 61.42 | 248.72 | -311.57 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.67 | 59.89 | 247.62 | -316.99 | -1.69 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 461.04 | 405.84 | 398.02 | 392.42 | 112.71 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 322.87 | 184.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -66.54 | -40.18 | -5.79 | -23.11 | 91.62 |
Net Cash from Financing Activities | 394.50 | 365.66 | 392.24 | 692.18 | 388.54 |
Effect of Exchange Rate Changes | 0.14 | -0.49 | -2.02 | 0.36 | 0.00 |
Net Change In Cash & Equivalents | -200.78 | -88.68 | 74.71 | 215.06 | 175.72 |
Cash at Beginning of Period | 553.07 | 641.76 | 567.05 | 351.99 | 176.27 |
Cash at End of Period | 352.30 | 553.07 | 641.76 | 567.05 | 351.99 |
Diluted Net EPS | -4.45 | -6.15 | -8.84 | -4.59 | -4.90 |
Fiscal Year End for Apellis Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -104.08 | -66.42 | -528.63 | -440.05 | -299.82 |
Depreciation/Amortization & Depletion | 10.14 | 6.59 | 28.00 | 1.44 | 14.03 |
Net Change from Assets/Liabilities | -109.67 | -103.50 | -200.17 | -157.61 | -100.11 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 62.29 | 30.35 | 106.07 | 99.37 | 58.12 |
Net Cash From Operating Activities | -141.32 | -132.98 | -594.74 | -496.86 | -327.78 |
Property & Equipment | -0.38 | -0.29 | -0.67 | -0.68 | -0.63 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.38 | -0.29 | -0.67 | -0.68 | -0.63 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 14.63 | 9.48 | 461.04 | 433.95 | 428.19 |
Issuance (Repayment) of Debt | 365.45 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -229.39 | 98.74 | -66.54 | -35.54 | -35.53 |
Net Cash from Financing Activities | 150.70 | 108.21 | 394.50 | 398.41 | 392.67 |
Effect of Exchange Rate Changes | 0.13 | -0.21 | 0.14 | -0.45 | 0.01 |
Net Change In Cash & Equivalents | 9.13 | -25.27 | -200.78 | -99.58 | 64.27 |
Cash at Beginning of Period | 352.30 | 352.30 | 553.07 | 553.08 | 553.08 |
Cash at End of Period | 361.43 | 327.03 | 352.30 | 453.50 | 617.34 |
Diluted Net EPS | -0.30 | -0.54 | -0.70 | -1.17 | -1.02 |